Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Director Michael C. Venuti sold 6,250 shares of the company’s stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $3.48, for a total value of $21,750.00. Following the completion of the sale, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $174,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded down 5.35% during midday trading on Monday, hitting $3.36. The stock had a trading volume of 947,938 shares. Infinity Pharmaceuticals Inc. has a 1-year low of $0.84 and a 1-year high of $6.63. The firm’s market cap is $169.43 million. The firm has a 50-day moving average price of $2.61 and a 200-day moving average price of $1.71.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Tuesday, March 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.11. Infinity Pharmaceuticals had a negative return on equity of 125.20% and a net margin of 13.23%. Infinity Pharmaceuticals’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same period last year, the company earned ($0.80) earnings per share. On average, equities analysts anticipate that Infinity Pharmaceuticals Inc. will post ($1.12) EPS for the current fiscal year.
Your IP Address:
Several hedge funds have recently added to or reduced their stakes in INFI. Evercore Wealth Management LLC raised its stake in Infinity Pharmaceuticals by 14.0% in the second quarter. Evercore Wealth Management LLC now owns 107,091 shares of the company’s stock worth $142,000 after buying an additional 13,157 shares during the last quarter. Tudor Investment Corp Et Al raised its stake in shares of Infinity Pharmaceuticals by 738.5% in the fourth quarter. Tudor Investment Corp Et Al now owns 165,998 shares of the company’s stock valued at $224,000 after buying an additional 146,200 shares in the last quarter. Oxford Asset Management raised its stake in shares of Infinity Pharmaceuticals by 63.5% in the fourth quarter. Oxford Asset Management now owns 343,172 shares of the company’s stock valued at $463,000 after buying an additional 133,310 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of Infinity Pharmaceuticals during the third quarter valued at about $905,000. Finally, Numeric Investors LLC raised its stake in shares of Infinity Pharmaceuticals by 5.6% in the fourth quarter. Numeric Investors LLC now owns 779,899 shares of the company’s stock valued at $1,053,000 after buying an additional 41,605 shares in the last quarter. Institutional investors own 79.56% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.